Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome

Morgan Stanley Thinks CVS Surcharge May Replace Lost Tobacco Revenue


CVS Health Corp's (NYSE: CVS) could get up to a 6 percent boost in retail revenue from its plan to add a surcharge to prescriptions filled through its benefits management network by pharmacies that sell tobacco, an analyst said Wednesday.

CVS, which recently stopped selling tobacco, on Tuesday unveiled the pilot program for its Caremark pharmacy benefits management business with more than 65 million members.

Morgan Stanley's Ricky R. Goldwasser called the plan a "$3.6 billion revenue opportunity" for CVS and said it represents a risk to Walgreen Company (NYSE: WAG) and Rite Aid Corporation (NYSE: RAD), both of which continue to sell tobacco and fill prescriptions managed by Caremark.

Separately, other analysts have estimated that by discontinuing tobacco sales, CVS is foregoing $2 billion in annual revenue.

The company hopes to outweigh the loss from tobacco sales partly by currying favor with public and private health insurers that are Caremark customers.

CVS said Tuesday that the surcharge plan comes at the request of customers it didn't identify.

Revenues from CVS' pharmacy benefits management segment increased 16.2 percent in the quarter ended June 30 to $21.8 billion. Revenues in its retail segment grew 4.5 percent to $16.9 billion.

The surcharge plan "may increase pressure" on Walgreen and Rite Aid to stop selling tobacco, Goldwasser said.

CVS is expected to post earnings on November 4 of $1.13 per share, up 11 percent from a year earlier, on revenue of $34.73 billion.

CVS traded recently at $83.22 a share, up 0.4 percent.

Latest Ratings for CVS

May 2019MaintainsBuyBuy
Apr 2019MaintainsOverweightOverweight
Apr 2019MaintainsStrong BuyStrong Buy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color News Retail Sales Analyst Ratings


Related Articles (CVS + RAD)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Tupperware Posts Weaker-Than-Expected Q3 Profit, Issues Weak Forecast

Organic Food Stocks Trending Lower Following Boulder Brands Guidance